Company profile: Attralus
1.1 - Company Overview
Company description
- Provider of biopharmaceutical therapies and imaging agents targeting amyloid and misfolded protein aggregates, including AT-02, a humanized IgG1 antibody fused with a pan-amyloid peptide to stimulate immune removal; AT-01 PET/CT and AT-05 SPECT agents for detecting amyloid deposits; AT-06 preclinical CAR-monocyte therapy; and a neurodegeneration program targeting Aβ, Tau, and α-Synuclein.
Products and services
- AT-01: Attralus develops an iodine-124 evuzamitide amyloid-specific imaging agent for PET/CT, detecting multiple types of amyloid deposits in major organs
- AT-02: Attralus engineers a humanized IgG1 monoclonal antibody fused with a pan-amyloid binding peptide, binding multiple types of amyloid deposits and stimulating the immune system to remove them
- AT-05: Attralus produces a technetium-99m labeled pan-amyloid binding peptide for SPECT imaging to support broader screening and diagnosis of systemic amyloidosis
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Attralus
Sparrow Pharmaceuticals
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical therapies for disorders of corticosteroid excess, including SPI-62, an oral HSD-1 inhibitor designed to reduce intracellular cortisol in conditions like endogenous Cushing’s syndrome and autonomous cortisol secretion, and SPI-47, combining SPI-62 with prednisolone for autoimmune diseases such as polymyalgia rheumatica.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sparrow Pharmaceuticals company profile →
Greer Laboratories
HQ: United States
Website
- Description: Provider of subcutaneous immunotherapy and allergenic extracts for allergy diagnosis and treatment, including non-standardized extracts; short ragweed pollen and short/giant ragweed pollen mix extracts; standardized cat hair extracts for asthma, rhinitis, and conjunctivitis; and standardized grass pollen extracts for skin test diagnosis and immunotherapy to reduce allergic symptoms.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Greer Laboratories company profile →
Amunix
HQ: United States
Website
- Description: Provider of biopharmaceutical research and development, discovering, designing, and developing novel biologics, protein, and peptide therapeutics, with a focus on prodrugs that enable potent immune-activating biotherapeutics for patients with solid tumor cancers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Amunix company profile →
Cellenkos
HQ: United States
Website
- Description: Provider of clinical-stage allogeneic cord blood regulatory T cell therapeutics for autoimmune and inflammatory disorders, enabled by the proprietary CRANE platform for cell enrichment and differentiation and in-house cGMP manufacturing. Pipeline includes CK0801 for bone marrow failure syndromes, CK0802 for COVID-19 ARDS, and CK0804 for myelofibrosis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cellenkos company profile →
Amira Pharmaceuticals
HQ: United States
Website
- Description: Provider of small-molecule pharmaceutical research focused on the discovery and early development of new drugs to treat inflammatory disease, leveraging unparalleled insights into bioactive lipid pathways and complex signaling processes controlling conditions including asthma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Amira Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Attralus
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Attralus
2.2 - Growth funds investing in similar companies to Attralus
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Attralus
4.2 - Public trading comparable groups for Attralus
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →